Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- April Drug Price Revision “Will Be a Hard One” for the Industry: Pharma Leader Nakayama
January 7, 2016
- JPWA President Expresses Opposition to Market Price Survey in Conjunction with Sales Tax Hike, Calls for “Simplified Survey” If Necessary
January 6, 2016
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
- FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
- Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
December 25, 2015
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
- JPMA Reprimands Novartis over Side Effect Reporting Violation
December 18, 2015
- JPMA to Watch Regulators’ Moves to Decide Its Action on Kaketsuken
December 18, 2015
- JPMA Says Re-Pricing of Huge-Seller Drugs Unreasonable, Preparing Statement
December 18, 2015
- Lilly’s Jonsson to Become Japan Chief of PhRMA
December 18, 2015
- PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
- JGA Chief Opposes 50% First Generic Pricing for Non-Oral Drugs with Adoair, Symbicort Generics in Mind
December 11, 2015
- JPMA Sets to Respond Harshly to Kaketsuken Cover-Up: Chief
December 8, 2015
- JPMA Requests on Price Revisions, Tax Seem to Have Sunk in for Politicians: Exec
November 20, 2015
- 6 Insurers Tender Request for FY2016 Reform, Say Healthcare Costs Must Be Cut with HTA, Generics
November 19, 2015
- Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
- Pharma Leaders Rev Up Lobbying Campaigns ahead of Year-End Budget, Tax Debates
November 18, 2015
- FPMAJ Gives Up on Crafting Rules for Disclosing Joint Generic Developers
October 27, 2015
- Reflect Industry Opinions in Pilot Introduction of Cost-Effective Assessments: JPMA
October 27, 2015
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…